Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 16 11:58AM ET
3.97
Dollar change
-0.04
Percentage change
-1.00
%
IndexRUT P/E- EPS (ttm)-2.76 Insider Own18.87% Shs Outstand82.29M Perf Week24.84%
Market Cap382.03M Forward P/E- EPS next Y-1.58 Insider Trans4.24% Shs Float78.07M Perf Month25.63%
Income-226.56M PEG- EPS next Q-0.45 Inst Own54.43% Short Float1.05% Perf Quarter-9.15%
Sales68.62M P/S5.57 EPS this Y35.71% Inst Trans4.65% Short Ratio1.01 Perf Half Y86.38%
Book/sh-2.35 P/B- EPS next Y16.48% ROA-58.42% Short Interest0.82M Perf Year162.91%
Cash/sh2.43 P/C1.63 EPS next 5Y15.80% ROE-705.53% 52W Range0.36 - 6.04 Perf YTD139.16%
Dividend Est.- P/FCF- EPS past 5Y84.52% ROI- 52W High-34.27% Beta1.64
Dividend TTM- Quick Ratio4.35 Sales past 5Y91.46% Gross Margin92.27% 52W Low1003.06% ATR (14)0.32
Dividend Ex-Date- Current Ratio4.61 EPS Y/Y TTM-9.52% Oper. Margin-217.40% RSI (14)61.59 Volatility9.00% 10.30%
Employees162 Debt/Eq- Sales Y/Y TTM-62.38% Profit Margin-330.17% Recom1.43 Target Price10.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q23.23% Payout- Rel Volume0.41 Prev Close4.01
Sales Surprise0.05% EPS Surprise-0.76% Sales Q/Q-4.94% EarningsMay 06 BMO Avg Volume812.74K Price3.97
SMA2026.90% SMA5011.35% SMA20039.15% Trades Volume136,691 Change-1.00%
Date Action Analyst Rating Change Price Target Change
May-30-24Initiated Cantor Fitzgerald Overweight
Mar-28-24Initiated Guggenheim Buy $11
Aug-10-23Upgrade JP Morgan Underweight → Neutral
Apr-24-23Downgrade BofA Securities Neutral → Underperform $7 → $2
Dec-06-22Initiated CapitalOne Overweight $12
Nov-09-22Downgrade BofA Securities Buy → Neutral $14 → $7
Sep-21-22Initiated JP Morgan Overweight $5
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $11
Nov-09-21Initiated Wolfe Research Outperform $44
Aug-17-21Resumed Jefferies Buy $40
Jul-11-24 03:24PM
Jul-08-24 02:00AM
Jul-01-24 04:05PM
Jun-27-24 07:15AM
Jun-13-24 02:31PM
04:05PM Loading…
Jun-03-24 04:05PM
May-30-24 07:15AM
May-15-24 07:15AM
May-09-24 07:01PM
07:15AM
May-07-24 08:55AM
08:44AM
May-06-24 10:53AM
08:22AM
07:30AM
07:20AM Loading…
07:20AM
06:55AM
06:10AM
06:00AM
May-01-24 04:05PM
07:00AM
Apr-16-24 08:30AM
Apr-04-24 07:00AM
Apr-03-24 07:00AM
Apr-01-24 04:05PM
Mar-15-24 12:30PM
Mar-14-24 05:16AM
Mar-13-24 08:51AM
08:20AM
07:00AM
07:15AM Loading…
Mar-06-24 07:15AM
07:00AM
Mar-05-24 05:45PM
Feb-27-24 07:00AM
Feb-20-24 10:00AM
Feb-16-24 03:57AM
Feb-15-24 11:57AM
Feb-08-24 01:15PM
Jan-19-24 01:05PM
09:40AM
Jan-04-24 10:05AM
07:15AM
07:00AM
Dec-12-23 05:15AM
Nov-20-23 02:40AM
Nov-15-23 03:00AM
Nov-08-23 01:26PM
01:03AM
Nov-07-23 08:15AM
07:15AM
07:00AM
Nov-06-23 07:00AM
Nov-02-23 05:50PM
10:10AM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-24-23 07:00AM
Oct-04-23 04:00AM
Sep-05-23 07:00AM
Aug-30-23 07:33PM
Aug-14-23 10:51AM
Aug-11-23 10:53AM
Aug-10-23 10:31AM
Aug-09-23 12:09PM
Aug-08-23 11:01PM
10:48AM
08:15AM
07:00AM
Aug-07-23 05:25PM
Aug-04-23 08:40AM
08:12AM
Aug-03-23 11:48AM
11:45AM
08:02AM
Aug-02-23 12:45PM
12:42PM
Aug-01-23 10:45AM
07:22AM
07:00AM
Jul-28-23 08:02AM
Jul-26-23 08:52AM
Jul-24-23 01:20PM
11:12AM
07:21AM
Jul-21-23 01:22PM
07:44AM
Jul-20-23 04:05PM
Jul-19-23 09:59AM
Jul-18-23 11:04AM
Jul-17-23 10:59AM
10:06AM
Jul-14-23 10:56AM
09:55AM
08:03AM
Jul-13-23 09:35AM
07:08AM
Jul-12-23 10:27AM
Jul-11-23 12:50PM
10:24AM
07:17AM
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLC10% OwnerJul 01 '24Buy2.81400,0001,124,00015,669,217Jul 03 08:00 PM
Redmile Group, LLC10% OwnerJul 01 '24Buy2.81400,0001,124,00012,995,040Jul 03 08:00 PM
Azelby RobertDirectorJun 17 '24Sale2.896,99520,21653,005Jun 18 09:45 PM
BIZZARI JEAN-PIERREDirectorJun 17 '24Sale2.896,99520,21679,502Jun 18 09:43 PM
Sandor VictorDirectorJun 17 '24Sale2.896,99520,21680,886Jun 18 09:37 PM
Squarer RonDirectorJun 17 '24Sale2.896,99520,21680,663Jun 18 09:35 PM
Monges VivianeDirectorJun 17 '24Sale2.891,4374,153106,627Jun 18 09:40 PM
Pfisterer ThomasDirectorJun 17 '24Sale2.891,4374,153213,900Jun 18 09:38 PM
Hug PeterDirectorJun 17 '24Sale2.891,1933,448182,644Jun 18 09:41 PM
MALLIK AMEETChief Executive OfficerMay 07 '24Sale4.4829,731133,1951,167,348May 09 04:06 PM